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http://dx.doi.org/10.1016/j.ccr.2013.05.009SUMMARYTherapeutic resistance in melanoma and other cancers arises via irreversible genetic, and dynamic pheno-
typic, heterogeneity. Here, we use directed phenotype switching in melanoma to sensitize melanoma cells
to lineage-specific therapy.We show thatmethotrexate (MTX) inducesmicrophthalmia-associated transcrip-
tion factor (MITF) expression to inhibit invasiveness and promote differentiation-associated expression of the
melanocyte-specific Tyrosinase gene. Consequently, MTX sensitizes melanomas to a tyrosinase-processed
antifolate prodrug 3-O-(3,4,5-trimethoxybenzoyl)-()-epicatechin (TMECG), that inhibits the essential
enzyme DHFR with high affinity. The combination of MTX and TMECG leads to depletion of thymidine pools,
double-strand DNA breaks, and highly efficient E2F1-mediated apoptosis in culture and in vivo. Importantly,
this drug combination delivers an effective and tissue-restricted antimelanoma therapy in vitro and in vivo
irrespective of BRAF, MEK, or p53 status.INTRODUCTION
Cancer initiation arises via the stepwise acquisition of mutations
that suppress senescence and promote cell division to lead to tu-
mor formation. Subsequently, cells within the primary tumor may
acquire properties of invasiveness and metastasize to seed new
tumors. Despite several decades of research, almost half of pa-
tients diagnosed with cancer die of the disease, primarily
because of metastases, and surgery remains the most effective
therapy. The failure of current approaches to cancer therapy re-
flects an underlying problem that has long been recognized (Fi-
dler, 1978), but which is only beginning to be understood at the
molecular level: cancer cell population heterogeneity. IrreversibleSignificance
There is currently no effective long-term treatment for metasta
hibitors occurs within some months, and there is no effective
chemotherapy may arise from the presence of invasive slow-c
strategy applied here uses methotrexate, a drug already in w
an invasive state, and then targets an essential enzyme in a me
As a result, we describe a potent antimelanoma therapy that is h
status and validate the concept of directed phenotype switchaccumulation of genetic lesions may give rise to cell populations
with a capacity to bypass therapies targeted specifically toward
key molecules. Superimposed on genetic variation is reversible
heterogeneity dictated by microenvironmental signaling; within
tumors, multiple subpopulations of cancer cells may coexist,
each with differing biological properties. Some may exhibit fea-
tures of differentiation, others proliferate, whereas some may
possess stem cell-like properties (Brabletz et al., 2005; Visvader
and Lindeman, 2008), able to initiate new tumors and provide a
pool of therapeutically resistant cells (Blagosklonny, 2005). For
therapies to be effective, two key criteria should be fulfilled: the
therapy should be effective independent of the driver mutations
within the cancer, so as to avoid resistance arising from genetictic melanoma; resistance to the recently developed BRAF in-
therapy for BRAF-negative melanomas where resistance to
ycling melanoma stem-like cells. By contrast, the two-step
idespread clinical use, to direct melanoma cells away from
lanoma-specific fashion to induce highly efficient apoptosis.
ighly effective in preclinical trials irrespective ofBRAF or p53
ing as a therapeutic option.
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Phenotype Switching in Melanomadiversity within signaling pathways, and potentially resistant
phenotypic subpopulations should be directed toward a sensi-
tive phenotype. Understanding the origins of cancer cell hetero-
geneity and how it can be managed to provide more effective
treatments is therefore a key issue.
Melanoma, a highly aggressive skin cancer with very poor
prognosis formetastatic disease, is driven bymutations that acti-
vate mitogen-activated protein kinase (MAPK) signaling, com-
bined with senescence bypass (Bennett, 2008; Lopez-Bergami,
2011). Around 50% of melanomas bear activating mutations in
BRAF (Davies et al., 2002), whereas a further 15%–20% express
activated NRAS (van Elsas et al., 1995), and a lower proportion
activation of MEK (Nikolaev et al., 2012), or other factors that
activate MAPK signaling such as Kit (Curtin et al., 2006) or
GNAQ (Van Raamsdonk et al., 2009). Consistent with genetic
heterogeneity playing a major role in therapeutic resistance, tar-
geting activated BRAF with vemurafenib leads to dramatic and
rapid tumor regression that relapses after somemonths (Sosman
et al., 2012; Villanueva et al., 2011), with resistance arising from
activating mutations in other factors that bypass the requirement
for activated BRAF in MAPK signaling (Fedorenko et al., 2011;
Nazarian et al., 2010). Although combining BRAF inhibition with
molecules that target other components of the MAPK pathway
is currently being investigated (Smalley and Flaherty, 2009), it
is clear that even for targeted therapies, genetic heterogeneity
represents a major challenge to effective therapy. An alternative
strategy, that would bypass the genetic resistance arising from
targeting specific components of the MAPK pathway, would be
to identify compounds that act on all melanomas irrespective
of how MAPK signaling is activated.
Advances in understanding the genetics underpinning mela-
noma progression have been complemented by observations
that the microphthalmia-associated transcription factor (MITF)
(Arnheiter, 2010; Hodgkinson et al., 1993) acts as a rheostat in
determining subpopulation identity (Carreira et al., 2006; Cheli
et al., 2012; Hoek and Goding, 2010). In melanomas, reduced
MITF expression leads to G1 arrested, invasive cells with
stem-like properties (Carreira et al., 2006; Cheli et al., 2011),
including the ability to initiate tumors with high efficiency. Low
levels of MITF, driven by transcriptional repression by the
BRN-2 (POU3f2) transcription factor (Goodall et al., 2008; Kobi
et al., 2010), lead to a p27-mediated cell-cycle arrest and an
invasive stem cell-like phenotype (Carreira et al., 2006; Cheli
et al., 2011; Pinner et al., 2009). By contrast, elevatedMITF leads
to activation of differentiation genes driving melanin production
such as TYROSINASE (TYR) and melanosome biogenesis (Car-
reira et al., 2005; Cheli et al., 2010; Loercher et al., 2005). Conse-
quently, tumors comprise a mix of MITF-positive and negative
melanoma cells (Goodall et al., 2008). As such, modulation of
MITF expression represents one approach toward driving het-
erogeneous populations of tumor cells to a therapeutically sen-
sitive phenotype.
Although MITF is required for melanoma proliferation (Carreira
et al., 2006), and has been described as a lineage addiction
oncogene, decreasing MITF expression as proposed (Garraway
et al., 2005) would potentially lead to an increase in invasive mel-
anoma cells (Carreira et al., 2006; Cheli et al., 2011). Here, we
take the opposite approach to therapy and screen for molecules
that upregulate MITF, with the aim of eradicating invasive106 Cancer Cell 24, 105–119, July 8, 2013 ª2013 Elsevier Inc.melanoma cells and at the same time sensitizing cells to a
TYR-processed antifolate prodrug 3-O-(3,4,5-trimethoxyben-
zoyl)-()-epicatechin (TMECG).
RESULTS
Methotrexate Stimulates MITF Expression to Induce
Differentiation in Melanoma Cells
MITF’s role in determining melanoma cell phenotype suggested
a two-step therapeutic approach (Figure 1A) that would
circumvent many problems associated with both genetic and
phenotypic heterogeneity. First is to elevate MITF expression
to eradicate invasive cells and then to use theMITF-inducedme-
lanocyte-specific enzyme TYR to activate a prodrug able to
target an enzyme critical to cell viability in a cell-type-specific
fashion. We therefore screened for molecules that elevate
MITF levels and identified methotrexate (MTX), a differentiating
agent and slow-tight binding competitive inhibitor of dihydrofo-
late reductase (DHFR) in widespread clinical use, as an effective
activator of MITF expression. After treating melanoma cells with
MTX, the level of MITF messenger (mRNA) was increased
compared to untreated controls in three melanoma cell lines
(Figure 1B). MITF protein levels were also upregulated in human
(SK-MEL-28, G361, A375) and murine (B16/F10) MTX-treated
melanoma cells as shown by western blot (Figure 1C), and by
confocal microscopy analyses in 501 MEL cells (Figure 1D).
Importantly MTX also upregulated MITF expression in the ame-
lanotic and highly invasive melanoma cell line IGR39 (Figure 1C,
lower panel), and consistent with our predictions,MTX-mediated
upregulation of MITF prevented invasiveness of both SK-MEL-
28 and IGR39 cells in a matrigel Boyden chamber assay (Fig-
ure 1E). The reduction in invasiveness on MTX addition was
mediated by increased MITF expression, because small-inter-
fering-RNA (siRNA)-mediated depletion of MITF reversed the ef-
fect of MTX (Figure S1 available online).
To determine whether MTX-induced changes in MITF levels
were accompanied by an increase in the transcriptional activity
ofMITF,weperformedchromatin immunoprecipitation (ChIP) as-
says to determine the occupancy of this transcription factor on
the promoters of the PMEL17 and TYR genes, both well-
characterized MITF targets (Cheli et al., 2010; Du et al., 2003)
(Figure 2A). Compared with untreated SK-MEL-28 cells, MTX
substantially increased the occupancy of MITF on the TYR pro-
moter (from1.5% in untreated cells to 25.2% inMTX-treated cells
with respect to an input control) and on the promoter/enhancer of
the Pmel17 gene (from 5.4% in untreated cells to 45.4% in MTX-
treated cells with respect to an input control). No binding was
observed to control regions lacking MITF target sites.
Using scanning electron microscopy (Figure 2B), we observed
that a single treatment with MTX strongly stimulated melanoma
cell dendricity, a morphological feature of differentiated melano-
cytes controlled by MITF (Carreira et al., 2005; Tachibana et al.,
1996) and the first observable parameter of melanoma cell differ-
entiation (Serafino et al., 2004). Consistent with these data,
quantitative real-time RT-PCR (Figure 2C) revealed that MTX
increased mRNA expression of the MITF differentiation targets
TYR, PMEL17, RAB27a, TYRP1, and MART1 (Cheli et al.,
2010) that was prevented by MITF-specific siRNA. The
increased mRNA expression of MITF targets was matched by
Figure 1. MTX Upregulates the Expression of MITF and Blocks Invasiveness
(A) The MITF rheostat and the two-step strategy for melanoma therapy. Drug A inducesMITF, eliminating invasive cells and driving cells to be sensitive to drug B.
(B) MTX (1 mM) increasesMITFmRNA determined using quantitative and conventional RT-PCR from indicated cell lines. Asterisks denote statistically significant
differences (p < 0.05).
(C) MTX (1 mM) induces MITF protein assayed by western blotting (WB) (*p < 0.05).
(D) Immunofluorescence of control or MTX-treated (3 hr) 501 MEL cells using anti-MITF and DAPI. Scale bar refers to all panels.
(E) Matrigel assay of control and MTX-treated SK-MEL-28 (48 hr, 1 mM) and IGR39 (72 hr, 1 mM) cells. Asterisks denote statistically significant differences (*p <
0.05). Scale bar refers to all panels.
Error bars in the entire figure show mean ± SD.
See also Figure S1.
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Figure 2. MTX Promotes Melanoma Differentiation
(A) Chromatin immunoprecipitation on TYR and Pmel17 genes of vehicle and MTX-treated (4 hr, 1 mM) SK-MEL-28 with semiquantitative PCR after immuno-
precipitation (upper panel) or quantitative real-time PCR (graphs) with IgG, or MITF and HDAC3 antibodies. Error bars indicate SDs of triplicates; experiment
reproduced four times with similar results. Primers were used to amplify the promoter and control regions of TYR and PMEL17 genes.
(B) Scanning electron micrographs of control and MTX-treated (1 mM, 24 hr) SK-MEL-28 cells. Scale bar is applicable to both panels.
(C) Quantitative RT-PCR of TYR, TYRP1, PMEL17,MART1, and RAB27amRNA. SK-MEL-28 and siMITF-SK-MEL-28 cells were treated for 5 hr with 1 mMMTX.
mRNA levels are presented relative to b-actin mRNA and compared to their expression levels in untreated cells (1-fold). Induction of all genes by MTX was
statistically significant (p < 0.05), except in siMITF-SK-MEL-28 cells.WB indicates efficiency ofMITF knockdown usingMITF-specific stealth RNA oligonucleotide
(siMITF) compared to control (siCN).
(D)WB for TYR in indicated cell lines (upper panels) following MTX treatment for indicated times; and immunofluorescence for TYR (green) and the melanosome
stage II marker, HMB45 (red) (lower panels), in SK-MEL-28 cells before (control) and after MTX (1 mM 3 hr) treatment. DAPI is represented in blue. Scale bar is
applicable to both panels.
(E) WB of MART1 protein levels in melanoma cell lines (*p < 0.05) following MTX treatment (1 mM).
Error bars in the entire figure show mean ± SD.
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cell lines, including the amelanotic cell line IGR39, as detected
by either western blot or immunofluorescence (Figure 2D) and
MART1 (Figure 2E).108 Cancer Cell 24, 105–119, July 8, 2013 ª2013 Elsevier Inc.MTX-Induced MITF Expression Renders Melanomas
Sensitive to Prodrug Therapy
The increased TYR expression in response to MTX-mediated
MITF activation provided an opportunity to implement the
Figure 3. A Combined Treatment with MTX and TMECG Inhibits Melanoma Growth and Induces Apoptosis in Cultures of Human Cells
(A) The intracellular accumulation of TMECG-QM species in SK-MEL-28 cells after 24 hr of treatment with 10 mM TMECG or 1 mMMTX plus 10 mM TMECG. The
left panel shows the HPLC-MS chromatograms.
(B) Proliferation assays performed using SK-MEL-28 of control cells or cells treated with indicated doses of MTX with or without 10 mM TMECG. Scale bar =
100 mm and refers to all panels.
(C) Quantification of effects of MTX/TMECG treatment on SK-MEL-28 cells (*p < 0.05 with respect to TMECG-treated cells [TMECG] = 10 mM). For time course
assay MTX (1 mM) and TMECG (10 mM) were used.
(D) Apoptosis determination at different MTX/TMECG combinations in SK-MEL-28 cells after 4 days of treatment. Data were obtained in triplicate in two in-
dependent experiments. Differences in apoptosis in MTX/TMECG-treated cells were significant with respect to individual treatments for each drug concentration
(p < 0.05).
(E) MTT assay indicating effects of MTX/TMECG (1 mM/10 mM) and PLX-4720 (1 mM) treatment on low passage patient-derived melanoma cells bearing indicated
MEK and BRAFmutations. Cells were treated with vehicle only (C), PLX-4720 (,), or with a combination of MTX + TMECG (6). Note the number of cells at the
start of the experiment was at the limit of detection.
(F) Effects of MTX/TMECG (1 mM/10 mM) on cell number of indicated cell lines.
Error bars show mean ± SD.
See also Figure S2 and Table S1.
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Phenotype Switching in Melanomasecond arm of the two-step strategy (Figure 1A). TMECG is an
antifolate prodrug (Sa´nchez-del-Campo et al., 2009a) we de-
signed to be activated by TYR, in effect generating a cell-type-
specific cytotoxic agent. HPLC-MS/MS experiments confirmedthat MTX-induced TYR overexpression greatly contributed to
the activation of the prodrug TMECG to its corresponding
quinone methide (TMECG-QM) (Figure 3A; Table S1) that acts
as a potent and irreversible competitive inhibitor of DHFR forCancer Cell 24, 105–119, July 8, 2013 ª2013 Elsevier Inc. 109
Figure 4. MTX and TMECG Combination Therapy Induces Apoptosis via dTTP Depletion and DNA Damage
(A) dTTP quantification in melanoma cells subjected to indicated treatments. *p < 0.05 with respect to untreated controls; **p = 0.001; ***Not statistically sig-
nificant with respect to the untreated controls.
(B) Quantification of all dNTPs in melanoma cells treated with MTX/TMECG (1 mM/10 mM).
(C) SK-MEL-28 cells treated with MTX (1 mM) and/or TMECG (10 mM), or X-rays (1 Gy) were examined by immunofluorescence for gH2AX foci (red) and DAPI
(blue). Scale bar = 7 mm and refers to all panels.
(D) Quantification of gH2AX foci in SK-MEL-28 cells treatedwithMTX (1 mM) and/or TMECG (10 mM), or X-rays. Histograms represent the positive gH2AX foci cells
and gH2AX foci/nucleus in positive gH2AX foci cells (*p < 0.01 when compared with untreated cells or those subjected to MTX and TMECG individuals treat-
ments).
(E) Detection of gH2AX by WB in SK-MEL-28 cells treated with MTX and/or TMECG. b-actin served as a protein loading control.
(legend continued on next page)
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Phenotype Switching in Melanomadihydrofolate (DHF) (Sa´nchez-del-Campo et al., 2009a). Treat-
ment of SK-MEL-28 cells with MTX alone reduced proliferation
but did not induce apoptosis, (Figure 3B, upper panels), consis-
tent with elevated MITF levels leading to reduced proliferation
(Carreira et al., 2005). By contrast, MTX at concentrations as
low as 10 nM in combination with TMECG led to substantial
apoptosis (Figure 3B, lower panels) and induced MITF expres-
sion (Figure S2A). The combination of a single dose of MTX and
TMECG was also highly effective, with apoptosis occurring in
close to 100% of cells after 4 days treatment (Figure 3C), and
titration of both compounds demonstrated they acted synergis-
tically (Figure 3D). Importantly, MTX/TMECG targetedmelanoma
cell lines independently of themutational status of genes such as
p53 (TP53) BRAF, NRAS, or PTEN and was also effective in the
amelanotic melanoma cell line IGR39 (Figure S2B). This raised
the possibility that MTX/TMECG would also be effective against
BRAF mutant melanomas that have developed genetic resis-
tance to BRAF and/or MEK inhibitors. We therefore tested the
effectiveness of MTX/TMECG on two low passage melanoma
cell lines (fewer than 10 passages) derived from patients with
activating BRAFmutations that are resistant to both BRAF-inhib-
itor andMEK-inhibitor therapy because they also have activating
mutations inMEK1 orMEK2 (Nikolaev et al., 2012). In these MTT
assays (Figures 3E and S2B), we used a low starting number of
cells (23 103) so that any proliferation could be readily visualized.
As expected, the PLX-4720 inhibitor of activated BRAF failed to
impact significantly on proliferation (Figure 3E). By contrast, the
MTX/TMECG combination therapy was highly effective. By
starting with 3 3 104 cells and counting cell numbers, the effec-
tiveness of MTX/TMECG in inducing cell death in these drug-
resistant cells was readily apparent (Figure 3F). Similar effects
were seen on melanoma cells derived from dissociated fresh
melanoma metastases isolated directly from patients (Fig-
ure S2C). To distinguish between melanoma and nonmelanoma
cells in the freshly dissociated tumors, we used a DOPA-
CHROMETAUTOMERASE (DCT) promoter-mCherry reporter vi-
rus that expressesmCherry only in themelanocyte lineage. In this
case, MTX/TMECG treatment for 6 days led to a 5-fold reduction
in mCherry-positive cells indicating effectiveness in cells directly
isolated from patient-derived tissue.
To verify that MTX/TMECG synergy is cell type specific, we
also performed titration experiments in melanoma (SK-MEL-
28, G361), breast (MCF7), and colon (Caco-2) cancer cell lines
(Figure S2D). As expected themelanoma cell lineswere substan-
tially less sensitive to MTX alone than the nonmelanoma lines.
The sensitivity to TMECG alone was between 2- and 5-fold
greater in the melanoma cell lines because both melanoma cell
lines express low levels of TYR. However, MTX synergistically
increased the sensitivity of the melanoma cells to TMECG,
presumably by upregulating MITF and TYR, whereas in the non-
melanoma cell lines the effects were at best additive. siRNA-
mediated depletion of MITF (Figure S2E), or TYR (Figure S2F),
substantially reduced cell death and confirmed their key require-
ment for the effectiveness of the MTX/TMECG drug combina-(F) Comet assay of SK-MEL-28 treated with vehicle or MTX/TMECG (1 mM/10 mM
Scale bar refers to both panels.
(G) Cell-cycle profile determined by flow cytometry of SK-MEL-28 cells treated w
Error bars show mean ± SD.tion. Thus, the synergy between the two compounds appears
limited to TYR-positive melanoma cells, a key aim in the design
of a cell-type-specific antimelanoma therapy.
MTX/TMECG Combination Therapy Promotes dTTP
Depletion and DNA Damage
The results so far indicate that, counterintuitively, two different
drugs that both target DHFR, synergistically kill melanoma cells.
DHFR is required for dTTP synthesis, and in most cancer cells its
inhibition by MTX leads to decreased dTTP levels (Wang et al.,
2005). By contrast in melanoma, MTX alone leads to increased
dTTP levels, whereas dTTP was significantly reduced by the
MTX/TMECG combination (Figure 4A), leading to a nucleotide
imbalance (Figure 4B). The ability of MTX to elevate dTTP in mel-
anoma, but not other cancer types may be partly explained by
the fact that DHFR is regulated by MITF (Strub et al., 2011;
data not shown), which is strongly upregulated by MTX. More-
over, because TMECG-QM acts as a competitive inhibitor of
DHFR with respect to DHF, the observed MTX-dependent
depletion of this substrate (Table S1) could explain the high syn-
ergy observed upon cotreatment with MTX and TMECG in mel-
anoma cells (Figures 3, S2B, and S2D) where TYR converts
TMECG to its quinone methide (Figure 3A).
Thymidine depletion induces DNA double-strand break (DSB)
formation (Pardee et al., 2004) characterized by phosphorylation
of histone H2AX at Ser139 (gH2AX) by ATM/ATR kinases and the
subsequent rapid formation of gH2AX foci at the DSB sites (Kin-
ner et al., 2008). Consistent with the effects of combination
treatment being mediated via thymidine depletion, immunofluo-
rescence revealed that combinedMTX/TMECG treatment of SK-
MEL-28 cells, but not MTX or TMECG alone, led to accumulation
of gH2AX foci by 48 hr (Figures 4C and 4D), a result confirmed by
western blotting (Figure 4E). The increase in gH2AX foci was
accompanied by the induction of DSBs as determined using a
comet assay (Figure 4F). Moreover, consistent with the MTX/
TMECG combination causing S phase-associated DNA dam-
age, sublethal doses of MTX/TMECG coupled with flow cytom-
etry revealed accumulation of cells in S phase (Figure 4G).
MTX/TMECG Combination Therapy Induces E2F1-
Mediated Apoptosis in Melanoma Cells
p53 is usually wild-type (WT) in melanoma (Box and Terzian,
2008). However, apoptosis triggered by MTX/TMECG was inde-
pendent of p53mutation status (Figures 5A and S2B). Consistent
with this, although p53 protein levels were upregulated by MTX/
TMECG, presumably as a consequence of DNA damage (Fig-
ure S3A), apoptosis was unaffected by p53 silencing (Figure 5A).
Although p53 mRNA levels in SK-MEL-28 cells did not change in
the presence of MTX/TMECG (Figure 5B), MTX and TMECG
combined dramatically induced the mRNA (Figure 5B) and pro-
tein expression (Figure 5B, lower panels) of the apoptosis prote-
ase-activating factor 1 (APAF1), as well as the mRNA (Figure 5B)
and protein (Figure 5C, lower panels) of the proapoptotic trans-
activating form of p73 (TAp73).) for 48 hr. Hydrogen peroxide was used as a positive control (data not shown).
ith a sublethal dose of MTX/TMECG.
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Figure 5. MTX/TMECG Treatment Induces E2F1 and p73
MTX (1 mM) and TMECG (10 mM) were used (for all changes *p < 0.05 with respect to individual treatments in all experiments). Error bars show mean ± SD.
(A) Indicated combinations of drugs were added to melanoma cell lines (p53 status indicated) and apoptosis determined after 3 days. p53 was silenced in G361
cells as indicated and shown in inset WB.
(B) Quantitative RT-PCR analysis of TAp73, p53, and Apaf1 (upper panel) in SK-MEL-28 treated with MTX and/or TMECG. Apaf1 protein levels are shown (lower
panel). b-actin was used as a protein loading control. mRNA levels are presented relative to b-actin mRNA.
(C) p73 protein levels were evaluated byWB over time following indicated treatments. b-actin expression indicated that an equal amount of protein was loaded for
each sample.
(D) WB of p-Chk1, p-Chk2, and E2F1 after MTX/TMECG treatment.
(E) Immunoprecipitation of E2F1 from control or MTX/TMECG-treated SK-MEL-28 cellsWB of immunoprecipitates using indicated antibodies. b-actin served as
a protein loading control.
(legend continued on next page)
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Phenotype Switching in Melanomap73 (TP73) expression is controlled by E2F1 (Dobbelstein
et al., 2005), which, in turn, is stabilized by phosphorylation by
Chk2 at Ser364, ATM kinase at Ser31, or acetylation by P/CAF
at lysines 117, 120, and 125 (Lin et al., 2001; Martı´nez-Balba´s
et al., 2000; Urist et al., 2004) (Figure S3B). DNA damage induced
by the MTX/TMECG combination led to a time-dependent
increase in Chk1 and Chk2 phosphorylation and increased
E2F1 protein (Figure 5D). Consistent with this, immunoprecipita-
tion of E2F1 revealed that MTX/TMECG increased its phosphor-
ylation and association with the P/CAF acetyl transferase
(Figure 5E).
Mass spectrometry analysis of immunoprecipitated E2F1
confirmed that MTX/TMECG increased both phosphorylation
(Figure S3C) and acetylation of E2F1, and also revealed loss of
methylation of E2F1 at Lys185 (Table S2) (Kontaki and Talianidis,
2010), a modification that inhibits acetylation, promotes E2F1-
degradation, and prevents stabilization of E2F1 in response to
DNA damage (Hallstrom et al., 2008). siRNA-mediated silencing
of E2F1 (Figure 5F) significantly decreased the sensitivity of SK-
MEL-28 cells to MTX/TMECG-induced apoptosis compared to a
control siRNA (siCN). Although we cannot rule out that E2F1
depletion blocks apoptosis by preventing passage to S phase,
collectively the data are consistent with a mechanism by which
manipulating MITF, and consequently TYR levels, via MTX treat-
ment renders melanoma cells sensitive to TMECG-induced
depletion of dTTP pools and p53-independent and E2F1-driven
apoptosis.
MTX/TMECG Is Highly Effective In Vivo
The profound effects of theMTX/TMECG combination in vitro led
us to test its antitumorigenic efficacy in vivo. First, we used a re-
constituted skin model of melanoma in which melanocytes were
replaced by A375 melanoma cells (Figure 6A). Twenty-one days
following tumor cell implantation, massive melanoma nodes
were observed within the epidermis, and evidence of early
metastasis into dermal structures was observed in untreated
skin. Both MTX and TMECG alone reduced, but did not abolish,
melanoma cell growth in this assay, consistent withMTX upregu-
lating MITF and slowing proliferation, and TMECG being
processed by low levels of TYR to inhibit DHFR. By contrast,
3D cultures were mostly free of melanoma cells after 14 days
of treatment with the MTX/TMECG combination.
In an independent approach, B16/F10 melanoma cells were
injected subcutaneously into C57BL/6 mice, a syngeneic mela-
noma model in which the host mice retain an intact immune sys-
tem that plays a major role in the evolution of human melanoma
(Zaidi et al., 2011). Compared to untreated mice, tumor growth
was significantly reduced by TMECG treatment, but not by
MTX treatment (Figures 6B and S4A). Tumors extracted from
MTX-treated mice were softer, easy to dissociate, and more
melanized than those obtained for vehicle-treated mice, consis-
tent with MTX-induced expression of MITF and TYR activity.
Strikingly however, the combination of MTX and TMECG acted
synergistically to inhibit tumor growth.(F) E2F1 shRNAs significantly inhibit MTX/TMECG-induced apoptosis in SK-MEL
TMECG before apoptosis quantification. Data are presented as percent apoptosis
experiments. Silencing of E2F1 was verified by WB: lane 1, siCN; lanes 2 and 3,
See also Figure S3 and Table S2.Because tumor volume is not always a direct indication of live
tumors cells (Figure S4A), we next employed a different mouse
melanoma model using B16/F10 melanoma cells expressing a
luciferase reporter (Figures 6C and S4B). Quantification of the
in vivo luminescence signal confirmed that the MTX/TMECG
combination was highly effective at reducing tumor burden.
Whereas MTX or TMECG alone had an approximately 2-fold ef-
fect, a synergistic reduction in luciferase was seen using the
combination (Figure S4B, left panels). Importantly, between
day 6 and day 12, MTX or TMECG alone led to decreased
numbers of melanoma cells in the tumors compared to
vehicle-treatedmice; however, by day 12 theMTX/TMECG com-
bination had reduced the number of melanoma cells within the
tumors compared to day 6, an indication of an effective thera-
peutic response (Figure S2B, right panel). B16/F10 tumors
treated with DMSO showed their usual histological appearance
of poor differentiation and limited necrosis (Figure 6D, upper
panel). In contrast, 14 days treatment withMTX/TMECG induced
obvious hemorrhagic necrosis, with necrotic areas of approxi-
mately 75% (Figure 6D, lower panels). Necrosis in splenic tumors
was less evident when mice were treated with MTX or TMECG
alone (4% ± 2%; and 11% ± 3%, respectively; data not shown).
Consistent with the results obtained in cultured melanoma cells,
MTX effectively induced MITF expression in mice as determined
by western blotting of tumors in vivo (Figure S4C, left panel) or
western blotting or immunofluorescence of dissociated tumor
cells (Figures S4C, right panel, and S4D, respectively).
Significantly any residual cells surviving MTX/TMECG treat-
ment in vivo retained their sensitivity to the drug combination.
Dissociated luciferase-tagged B16/F10 tumor cells from vehicle
or MTX/TMECG-treated mice were assayed for luciferase activ-
ity immediately after plating or 3 days later. Cells from both
vehicle and MTX/TMECG-treated animals were able to prolifer-
ate in culture in the absence of drug, but treatment with MTX/
TMECG retained its efficacy, reducing luciferase activity and
cell number up to 18-fold, irrespective of whether they were
derived from control or MTX/TMECG-treated mice (Figures 6E–
6G). Thus, any cells in vivo surviving MTX/TMECG treatment
do not appear to acquire genetic or phenotypic resistance to
the drug combination.
Because elevated MITF expression in response to MTX in-
hibits invasiveness (Figure 1E), we next tested whether MTX/
TMECG administration after injection of melanoma cells could
prevent melanoma dissemination from the spleen to the liver,
one of the preferential metastatic locations for melanomas.
Luciferase-tagged B16/F10 cells were injected into the spleens
of C57BL/6 mice, and, after 14 days treatment, tumor expansion
was measured. Luciferase imaging showed that MTX/TMECG-
treated mice had a substantially lower burden of macroscopic
liver metastases (Figure 7A), with no mice bearing >25 macro-
scopic liver metastases compared with controls (Figure 7B). His-
tological analysis of livers (Figure 7C) revealed that when calcu-
lated as the percentage of liver volume, metastatic volume was
55% ± 12% for vehicle and 6% ± 2% for MTX/TMECG-treated-28 cells. siCN- and siE2F1-transfected cells were treated for 3 days with MTX/
compared to MTX/TMECG-treated siCN cells (100%) from three independent
siE2F1 (shRNAs HSS103015 and HSS103016, respectively).
Cancer Cell 24, 105–119, July 8, 2013 ª2013 Elsevier Inc. 113
Figure 6. MTX and TMECG Combination Therapy Is Effective In Vivo
(A) A375 melanoma cells were included in a human reconstructed skin model and were treated with MTX (1 mM) and/or TMECG (10 mM) for 14 days. Medium,
containing the indicated drugs was replenished every other day. The ratios of tumor versus skin areas are indicated. *p < 0.05 when compared with vehicle-
treated skins. **p < 0.05 when compared with individual MTX and TMECG treatments. Scale bar = 150 mm and refers to all panels.
(B) B16/F10 melanoma cells were injected subcutaneously into C57BL/6 mice. Images show tumor size 17 days postinjection in control and treated mice. The
time-dependent evolution of tumors and the mean tumor area (±SD) after 21 days of treatment are shown. *p < 0.05; **p < 0.005; NS, not statistically significant.
(C) Luciferase imagingof control andMTX/TMECG-treatedmice12daysposttumorcell injection. Firefly luciferin (120mg/kgofmouse)was injected intraperitoneally.
The values (means ± SD) are representative of three independent experiments. *p = 0.007; **p = 0.002. Results of individual treatments are described in Figure S4.
(legend continued on next page)
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Phenotype Switching in Melanomamice (p = 0.002). These data were also confirmed by real-time
RT-PCR analysis designed to detect melanoma specific TYR
mRNA in mouse livers (Figure 7D). Thus, the MTX/TMECG com-
bination leads to a dramatic inhibition of melanoma growth both
in vitro and in vivo.
Finally, we also assessed MTX/TMECG combination for po-
tential toxicity in mice. After administration, neither MTX nor
TMECG affected the levels or clearance of the other compound
in plasma (Figures S5A and S5B, respectively; Table S3), and,
although high doses of MTX (10 mg/kg/day) induced some
weight loss in mice as expected, the doses of MTX used to treat
melanoma in this study alone (1 mg/kg/day) or in combination
with up to 50 mg/kg/day TMECG had no effect on mouse weight
(Figure S5C). Moreover, no obvious deleterious effect of theMTX
or TMECG combination was evident on nonmelanoma TYR- and
MITF-positive cells such as skin melanocytes (Figure 7E) or the
pigmented eye epithelia of the retina (RPE) and iris (IPE) (Fig-
ure 7F) presumably because unlike melanoma, these TYR/
MITF-positive cells are not proliferating and are therefore insen-
sitive to DHFR inhibition and dTTP depletion.
DISCUSSION
A major challenge in cancer therapy is to identify approaches
that take into account resistance dictated by both irreversible
genetic diversity and reversible microenvironment-driven
phenotypic heterogeneity. Melanoma affords an excellent model
system to explore such therapeutic options. Recent advances
have identified key genetic drivers of melanoma progression
and the origins of genetic resistance to targeted anti-BRAF ther-
apy. Moreover, because MITF-negative cells are invasive, have
stem-like properties, and are able to initiate tumors (Carreira
et al., 2006; Cheli et al., 2011; Hoek and Goding, 2010), therapies
that upregulate MITF have clear advantages.
The MTX/TMECG combination therapy used here (summa-
rized in Figure 8) is highly effective in vitro and in vivo and has
several key advantages compared to more conventional strate-
gies. First, by upregulating MITF, MTX potentially depletes the
pool of invasive melanoma cells that drive metastasis formation;
second, the effectiveness of the therapy is strictly dependent on
processing of the TMECG prodrug by TYR, a melanocyte-spe-
cific gene, thereby avoiding damage to other cell types, which
is a major disadvantage of conventional chemotherapies; third,
by inducing dTTP depletion through targeting an essential
enzyme, the MTX/TMECG combination therapy is effective in
melanoma cells irrespective of their BRAF or MEK status and
is not susceptible to resistance arising from genetic heterogene-(D) Sections stainedwith hematoxylin and eosin (H&E) staining show the effect ofM
DMSO (vehicle) orMTX/TMECG (1mg/kg/day and 50mg/kg/day, respectively) ov
MTX/TMECG-treated tumors showed hemorrhagic (H) necrosis with obvious divi
from two independent experiments (n = 5 for each experiment). Scale bar = 200
(E) B16/F10 melanoma cells, expressing a luciferase reporter, were injected sub
vehicle (DMSO) or MTX/TMECG (1mg/kg/day and 10mg/kg/day, respectively) ov
from tumors were examined for their sensitivity to the MTX/TMECG combination
panel).
(F) The histogram represents the number of B16/F10-luc2 cells remaining after 3 d
Mean ± SD was calculated in triplicate (NS, not statistically significant).
(G) The morphology of tumor dissociated B16/F10-luc2 cells before and after of
See also Figure S4.ity within the MAPK pathway, the major cause of resistance to
anti-BRAF therapies; and fourth, the proapoptotic effects of
dTTP depletion in response to MTX/TMECG is independent of
p53 status. Thus, the combination of MTX/TMECG overcomes
many of the genetic and phenotypic heterogeneity issues that
are major barriers to current antimelanoma therapy. Although
we did not detect resistance among the residual population of tu-
mor cells in MTX/TMECG-treated mice, resistance could poten-
tially arise, for example, via genetic or epigenetic inactivation of
TYR, E2F1, or p73. For this reason, as with any targeted therapy,
it is crucial to treat patients when the tumor burden is low,
because the heterogeneity that drives therapeutic resistance in-
creases with the number of cancer cells.
Importantly, MTX is in widespread clinical use for a variety of
steroid-recalcitrant inflammatory diseases, and our preliminary
observations indicate that TMECG alone or in combination
with MTX is not toxic in vivo, even to nonmelanoma pigment
cells, and exhibits good pharmacokinetic profiles. As such, the
MTX/TMECG combination therapy has potential for rapid appli-
cation in a human setting.
Our observation that MTX increases MITF expression, and
consequently the expression of multiple melanosomal compo-
nents, may also partly provide an explanation for the fact that
melanomas, compared to epithelial cells, are highly resistant to
the effects of MTX alone. Accumulating evidence indicates
that melanosomes, whose biogenesis is promoted by MITF,
contribute to the refractory properties of melanoma cells by
sequestering cytotoxic drugs and increasing melanosome-
mediated drug export. Moreover, folate-receptor-a (FRa)-medi-
ated endocytotic transport of MTX facilitates melanosomal drug
sequestration and cellular export in melanoma cells, thereby
reducing the accumulation of MTX in intracellular compartments
(Sa´nchez-del-Campo et al., 2009b). Thus MTX-driven upregula-
tion of MITF and consequent increased melanosome biogenesis
may promoteMTX resistance. In this respect, the combination of
TMECG in combination with MTX used here bypasses this bar-
rier to MTX monotherapy.
Although MTX upregulates MITF mRNA and protein expres-
sion, how MTX activates the MITF promoter is not fully under-
stood, though preliminary results (data not shown) indicate that
MTX upregulates expression of Sox10, a known regulator of
MITF expression (Lee et al., 2000). Nevertheless, MITF is neces-
sary for the synergy with TMECG to be achieved, but increased
expression of MITF in the absence of MTX would not be suffi-
cient; MTX plays additional roles including inducing E2F1 deme-
thylation and depletion of DHF pools that are key components of
MTX/TMECG combination therapy (see below). Moreover,TX/TMECGonB16/F10 primary splenic tumors. Xenograft tumors treatedwith
er 14 days. Vehicle-treated tumors showed no discernible necrosis (N), whereas
ding line between viable (T) and necrotic tissues. Representative images taken
mm and is applicable to both panels.
cutaneously to mice. Mice were divided in two groups (n = 7) and treated with
er 21 days. Then, tumors were pooled and dissociated. B16/F10 cells extracted
(1 and 10 mM, respectively) using quantification of the luminescence signal (left
ays of MTX/TMECG treatment with respect to vehicle-treated controls (100%).
MTX/TMECG treatment. Scale bar refers to all panels.
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Figure 7. MTX and TMECG Combination
Therapy Inhibits Metastasis and Does Not
Affect Nonmelanoma Pigment Cells In Vivo
(A) Bioluminescent imaging of livers at 14 days
postintrasplenic injection of B16-F10-luc2 cells
from untreated and MTX/TMECG-treated mice
are shown.
(B) Quantification of macrometastases (0–10, 10–
25, or >25) after treatment with vehicle (control),
MTX (1 mg/kg/day), and/or TMECG (50 mg/kg/
day). *Differences were statistically significant
with respect to vehicle-treated mice (p < 0.05).
**p < 0.005 when compared with TMECG-treated
mice.
(C) H&E-stained, 4 mm formalin-fixed, paraffin-
embedded liver sections from control (DMSO) and
MTX/TMECG-treated mice (1 and 50 mg/kg/day,
respectively).
(D) Histograms represent the number of copies of
TYR mRNA for every 1 3 103 copies of
b-actin ±SD of three independent experiments.
Mice were treated with vehicle, MTX (1 mg/kg/
day), and/or TMECG (50 mg/kg/day). Asterisks
show statistically significant differences when
compared with untreated controls (vehicle) (*p =
0.005; **p = 0.001) Livers from noninoculatedmice
(NT) were used as a control.
(E) Toxicological assays of the effect of MTX and/
or TMECG on skin melanocyte integrity. MTX/
TMECG treatment (20 days; 1 mg/kg/day and
50 mg/kg/day, respectively) did not influence
number and morphology of mouse skin mela-
nocytes. Error bars for histograms represent
means ± SD.
(F) Microscopic analysis (403 magnification) H&E
stain of mouse retina and retinal pigmented
epithelium (RPE) and MITF immunostaining (left
panel), or iridal melanocytes (IPE) (right panel),
indicating no obvious differences following
20 days MTX/TMECG treatment. Scale bar refers
to all panels.
See also Figure S5 and Table S3.
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important difference between the two drugs. It is well known
that antifolates like MTX deplete dTTP in sensitive cells; how-116 Cancer Cell 24, 105–119, July 8, 2013 ª2013 Elsevier Inc.ever, over several hours the endocy-
totic-mediated transport of MTX facili-
tates its cellular export, greatly reducing
intracellular MTX levels in melanoma
(Sa´nchez-del-Campo et al., 2009b).
However, as we show here, MTX, before
leaving the cells, modifies the posttrans-
lational status of E2F1 leading to its acti-
vation. E2F1 activation should, therefore,
allow S phase transition in cells, and
importantly for melanoma survival, cells
would recover an operative folate cycle
(see detailed model in Figure S6). In the
absence of exported MTX, high levels of
thymidylate synthase and DHFR would
impede the lethal depletion of dTTP
and, in turn, would produce a nucleotideimbalance that would favor dTTP excess. In addition, by
depleting the levels of folate receptor-alpha (FR-a), MTX also de-
pletes cellular pools of DHF, the natural substrate of DHFR.
Figure 8. Summary of MTX/TMECG Therapeutic Strategy
MTX activation of MITF and consequently TYR activates the melanoma-spe-
cific antifolate activity of TMECG, leading to depletion of cellular dTTP and
E2F1-mediated apoptosis. MTX therefore directs melanoma cells away from
an invasive state (see Figure 1A), and targeting DHFR, an essential enzyme, in
a melanoma-specific fashion induces highly efficient apoptosis in vitro and
in vivo. Note that whereas activation of TYR expression is associated with
differentiation, TYR-positive melanoma cells can proliferate. The dashed line
represents the inhibition of DHFR by MTX at early times in the treatment.
Although MTX is exported out of melanoma cells over several hours, it is likely
to inhibit DHFR prior to being exported from cells.
See also Figure S6.
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activity, is a competitive inhibitor of DHFR with respect to DHF,
this depletion may favor the irreversible binding of TMECG-QM
to its target enzyme, DHFR. Under these conditions, efficient in-
hibition of DHFR by TMECG-QM would lead to dTTP depletion
(Figure S6). In fact, we hypothesize that because MTX induces
cellular depletion of DHF in melanoma, combined therapies
could efficiently inhibit DHFR if antifolates were transported
into cells by an FRa-independent process, as is the case of
TMECG (Sa´ez-Ayala et al., 2012).
The results presented here also have implications for under-
standing the functionality of proapoptotic pathways in mela-
noma. Starvation of the DNA precursor, dTTP, kills bacterial
and eukaryotic cells alike. Despite numerous studies, the mech-
anism behind this toxicity remains unknown, although the incor-
poration of incorrect nucleotides and subsequent excision is the
most accepted explanation. Thus, cell death induced by dTTP
depletion has been associated with common pathways that
regulate apoptosis. The stabilization and subsequent accumula-
tion of the p53 tumor-suppressor has been proposed as the
signal that initiates apoptosis and prevents nucleotide misincor-
poration during DNA synthesis and repair (Elledge et al., 1995).
However, inhibitors of dTTP synthesis can cause apoptotic cell
death in cells lacking a functional p53 protein, suggesting the ex-
istence of p53-independent mechanisms of ‘‘thymineless’’
stress-induced apoptosis (Mun˜oz-Pinedo et al., 2001; Myers
et al., 2009; Rodriguez and Meuth, 2006; Sidi et al., 2008).
More recently, it has been proposed that ‘‘thymineless’’ death
may be mediated by the E2F1 apoptotic cascade (Wang et al.,
2005). Our results strongly favor this hypothesis and are consis-
tent with E2F1, CHK1, CHK2, and p73-mediated p53-indepen-
dent cell death occurring after the dTTP depletion/DNA damage
that was induced by the MTX/TMECG treatment of melanoma
cells.
In conclusion, by exploiting our in-depth knowledge of the
molecular mechanisms underlying phenotype switching in mela-
noma, we have developed a highly effective antimelanoma ther-
apy. Importantly, this therapy is likely to be effective in patientswith resistance to BRAF and MEK inhibitors and consequently
may have a major impact in eradicating BRAF-resistant cells
following anti-BRAF therapy.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
TMECG was synthesized from catechin (Sa´nchez-del-Campo et al., 2008).
MTX was obtained from Sigma (Madrid, Spain). Antibodies used in this study
are listed in Supplemental Experimental Procedures.
Cell Lines, Proliferation, and Apoptosis Assays
Cell lines were obtained from ATCC and maintained in the appropriate culture
medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cell
viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) cell proliferation assay. Apoptosis was determined
using an ELISA assay (Cell Death Detection ELISAPLUS, Roche) described
in more detail in Supplemental Experimental Procedures.
Tumor Dissociation
Whole subcutaneous melanoma tumors were resected en bloc, including the
overlying and immediate surrounding skin and subcutaneous tissue. Tumors
were then minced, mechanically disaggregated, and passed through a
100 mm filter using ice-cold RPMI1640 supplemented with 10% FBS, to
achieve a single cell suspension. Live cells were counted using trypan blue
and used for indicated experiments.
RNA Interference
Specific Stealth siRNAs for MITF (HSS142939 and HSS142940), E2F1
[HSS103015 (siRNA1) and HSS103016 (siRNA2)], and p53 (HSS129934 and
HSS129936) were obtained from Invitrogen and transfected into melanoma
cells using Lipofectamine 2000 (Invitrogen). TYR expression was knocked
down using specific human siRNAs (sc-36766; Santa Cruz Biotechnology)
and LipofectAMINE 2000 using standard protocols specified by the suppliers.
Treatments were started 24 hr after siRNA transfection. siRNA-negative con-
trols were used as control oligonucleotides, and the ability of the siRNA oligo-
nucleotides to knock down the expression of the selected genes was analyzed
by western blotting 24 hr after siRNA transfection.
Dinucleotide Triphosphate Pool Extraction and Analysis
Asynchronously proliferating SK-MEL-28 cells were seeded in 6-well dishes.
The extraction and analysis of the dinucleotide triphosphate (dNTP) pools in
each extract were carried out as described previously (Angus et al.,
2002).The reaction mixtures (50 ml) contained 100 mM HEPES buffer (pH 7.5)
10 mMMgCl2, 0.1 units of the Escherichia coli DNA polymerase I Klenow frag-
ment (Sigma), 0.25 mM oligonucleotide template, and 1 mCi [3H]dATP (ARC) or
[3H]dTTP (PerkinElmer). Incubation was carried out for 60 min at 37C.
Image Acquisition, Quantification of Western Blots, and Statistical
Analysis
Western blot and microscopy data have been repeated at least three times,
and similar results were obtained. The results from one experiment are shown.
For quantification, western blot results were scanned with a Bio-Rad Chemi-
Doc scanning densitometer (Bio-Rad). For other experiments, the mean ±
SD for five determinations in triplicate were calculated. Numeric data were
analyzed for statistical significance using Mann-Whitney test for comparison
of means with SPPS statistical software for Microsoft Windows, release 6.0
(Professional Statistic). Individual comparisons were made with Student’s
two-tailed, unpaired t test. The criterion for significance was p < 0.05 for all
comparisons.
Ethical Approvals
Human tumor samples were collected from patients attending the melanoma
service at Oxford University Hospital; all provided written informed consent.
The protocol was approved by Oxfordshire Research Ethics Committee C
(reference 09/H0606/5). All animal procedures were approved by the EthicalCancer Cell 24, 105–119, July 8, 2013 ª2013 Elsevier Inc. 117
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Phenotype Switching in MelanomaCommittee of the University of Murcia and the Direccion General de Ganaderia
y Pesca, Comunidad Autonoma de Murcia (Project reference A1311121507).
The following experimental procedures are described in Supplemental Infor-
mation: antibodies, PCR analysis, apoptosis assays, comet assay, invasion
assay, ChIP assays, immunoblotting and immunoprecipitation, microscopy,
MALDI-TOF mass spectroscopy, reconstituted skin, primary melanoma cells
and lentivirus infection, mouse melanoma models, pharmacokinetic studies,
and toxicology.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.05.009.
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